Nabriva Therapeutics plc Proceeds from Convertible Debt
Nabriva Therapeutics plc reported Proceeds from Convertible Debt of $3.44 million for the 12-month period ending 2015-12-31, per its 10-K filed 2018-03-16.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromConvertibleDebt · last filed 2018-03-16
- Nabriva Therapeutics plc proceeds from convertible debt for fiscal 2015 was $3.44M, a 27.14% decline from fiscal 2014.
- Nabriva Therapeutics plc proceeds from convertible debt for fiscal 2014 was $4.72M.
| Period end | Proceeds from Convertible Debt 12 month |
|---|---|
| 2015-12-31 | $3.44M 10-K · filed 2018-03-16 |
| 2014-12-31 | $4.72M 10-K · filed 2017-03-24 |